Title : Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.

Pub. Date : 2017 Jan

PMID : 28341109






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. lorvotuzumab mertansine neural cell adhesion molecule 1 Homo sapiens